Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Bepotastine Besilate in Allergic Conjunctivitis
NCT00586664Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- Oct 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bepotastine in allergic conjunctivitis (AC) (3 arms), sponsored by Bausch + Lomb. Primary endpoints: Ocular Itching at 16 hours and Conjunctival Redness at 16 hours. Started Oct 2007; status: completed.
02
Drugs
bepotastine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT00586664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00586664.